Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand.

Lee, Chang‐Keun, Lee, Eun Young, Chung, Son Mi, Mun, Se Hwan, Yoo, Bin, Moon, Hee‐Bom·2004·Arthritis & Rheumatism
DOI 10.1002/art.20637

Cited by (137)

Items 101–137 of 137

  1. Rapid and relaying deleterious effects of a gastrointestinal pathogen, Citrobacter rodentium, on bone, an extra-intestinal organ
    Kunal Sharan, Cordelia Brandt, Mohd Aslam Yusuf, Parminder Singh, Namrita Halder, Madeline Edwards, SVVS Ravi Mangu, Abhilipsa Das, Amrita Mishra, Shashi S. Kumar et al. · 2025 · iScience
  2. Anti citrullinated protein antibodies and mechanism of action of common disease modifying drugs--insights in pathomechanisms of autoimmunity.
    G. Pongratz, M. Fleck · 2012 · Current pharmaceutical design
  3. Osteoporosis in rheumatic diseases
    Lixia Gao · 2015 · World Journal of Rheumatology
  4. Effects of chloroquine and hydroxychloroquine on bone health (Review)
    Sok Kuan Wong · 2025 · Molecular Medicine Reports
  5. Remarkable improvement of the hip joint lesion in a patient with rheumatoid arthritis by the treatment with anti-TNF-.ALPHA. agents.
    Yasuaki Nagare, Koji Kinoshita, Fumiaki Nishisaka, Masakatsu Saito, Tohgo Nonaka, Masanori Funauchi · 2010 · Japanese Journal of Clinical Immunology
  6. Effect of methotrexate on the mandibular development of arthritic rabbits
    Thomas Michael Präger, Philipp Meyer, Smbat Rafayelyan, Kirsten Minden, Paul‐Georg Jost‐Brinkmann · 2014 · European Journal of Orthodontics
  7. Methotrexat als Kombinationspartner bei TNF-Inhibitoren und Tocilizumab
    Torsten Witte · 2013 · Zeitschrift für Rheumatologie
  8. Desirable and Adverse Effects of Antiinflammatory Agents on the Heart
    Massimo Imazio, Silvia Maestroni, A. Valenti, Véronique Laure Ramoni, Antonio Luca Brucato · 2017 · Elsevier eBooks
  9. Low-Dose Methotrexate and Bone Health: Pathophysiological and Clinical Perspectives
    Anton Sokhan, Judith Haschka, Zora Messner, Jochen Zwerina, Roland Kocijan · 2026 · Journal of Clinical Medicine
  10. Methotrexate
    Alyssa K. Johnsen, Michael E. Weinblatt · 2011 · Elsevier eBooks
  11. Adenosine blocks aminopterin-induced suppression of osteoclast differentiation
    Junpei Teramachi, Akiko Kukita, Pengfei Qu, Naohisa Wada, Yin-Ji Li, Seiji Nakamura, Toshio Kukita · 2012 · Journal of Bone and Mineral Metabolism
  12. Skeleton, Inflammatory Diseases of
    Daniel Aeberli · 2014 · Elsevier eBooks
  13. Chapter 80 – Treatment of Autoimmune Disease: Established Therapies
    Bevra Hannahs Hahn, Jennifer K. King · 2014
  14. Treatment of Autoimmune Disease
    Bevra Hannahs Hahn, Jennifer K. King · 2013 · Elsevier eBooks
  15. СONCENTRATION OF ANTI-INFLAMATORY CYTOKINES IN CELL CULTURE SUPERNATANTS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS
    Криволапова Ирина Михайловна, Пашнина Ирина Александровна, В. А. Черешнев · 2019 · Medical Immunology (Russia)
  16. Mizoribine may suppress bone erosion in patients with rheumatoid arthritis by inhibiting osteoclastogenesis
    Yeon-Ah Lee, Hyung-In Yang, Eunkyung Park, Jun Soo Bang, Hyun Mi Choi, Da Hee Oh, Sanghoon Lee, Seung‐Jae Hong, Yoon-Je Jo, Myung Chul Yoo et al. · 2009 · European Journal of Pharmacology
  17. The glycosphingolipid inhibitor eliglustat inhibits autophagy in osteoclasts to increase bone mass and reduce myeloma bone disease
    Houfu Leng, Hanlin Zhang, Linsen Li, Shuhao Zhang, Yanping Wang, Adel Ersek, Emma V. Morris, Erdinç Sezgin, Yi‐Hsuan Lee, Yunsen Li et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  18. Osteotropic cytokines : expression in human gingival fibroblasts and effects on bone
    Py Palmqvist · 2006 · KTH Publication Database DiVA (KTH Royal Institute of Technology)
  19. Potential role of pharmacogenetics for optimalization of drug therapy in rheumatoid arthritis
    Wouter M. Kooloos · 2009 · Leiden Repository (Leiden University)
  20. Einsatz von Tiermodellen in der kieferorthopädischen Forschung
    Thomas Michael Präger · 2015 · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver
  21. A case of juvenile idiopathic arthritis exhibiting repair of systemic bone erosion in response to continuation of MTX therapy after achievement of clinical remission
    Teruyuki Nakatani, Toru Maekawa, Shinsuke Ishii · 2011 · Modern Rheumatology
  22. PANNUS INVASION INTO CARTILAGE AND BONE IN RHEUMATOID ARTHRITIS
    Mari Ainola · 2009 · Työväentutkimus Vuosikirja
  23. Effects of Sulfasalazine Treatment in Juvenile Idiopathic Arthritis: Clinical and Radiological Observations
    Marion A. J. van Rossum · 2007 · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
  24. Methotrexat als Kombinationspartner bei TNF-Inhibitoren und Tocilizumab
    R. E. Schmidt, Hannover P. Lamprecht · 2013
  25. Repair of Bone Erosions in Two Patients with Recent-onset Rheumatoid Arthritis by Sulfasalazine Monotherapy
    Fumiaki Nishisaka, Tohgo Nonaka, Masakatsu Saito, Kanji Fukuda, Chiaki Hamanishi · 2010
  26. Artritis reumatoide del adulto: estrategias terapéuticas
    B. Combe, Cédric Lukas, J. Morel · 2016 · EMC - Aparato Locomotor
  27. Wybrane czynniki proapoptotyczne i antyapoptotyczne w młodzieńczym idiopatycznym zapaleniu stawów
    Karolina Adamczak · 2014
  28. Polyarthrite rhumatoïde de l'adulte : stratégies thérapeutiques
    Bernard G Combe, Christian Aljoscha Lukas, Jacques Morel · 2015
  29. Chapter 80 – Treatment of Autoimmune Disease: Established Therapies
    Bevra Hannahs Hahn, Jennifer K. King · 2014 · Academic Press eBooks
  30. Effects of salazosulfapyridine on the profile of cell surface proteins, revealed by biotinylation of cell surface proteins and 2-dimentional electrophoresis
    Kazuki Omoteyama, Toshiyuki Sato, Mitsumi Arito, Masaaki Sato, Naoya Suematsu, Manae Suzuki Kurokawa, Tomohiro Kato · 2018 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
  31. Iguratimod, A Synthetic Disease Modifying Anti- Rheumatic Drug (Sdmard), and Various Dmards Suppress Joint Destruction. The Pathophysiological Mechanisms of the Inhibition of Bone/Cartilage Destruction
    Kôichirô Ishikawa, Junichiro Ishikawa · 2018 · Journal of Bone Biology and Osteoporosis
  32. Sulfasalazine promotes myogenic differentiation via increasing of fast myosin heavy chain isoforms
    Seungju Cho, Seonggyu Choi, Hyunjun Chang, Nguyen Khoi Tran, Hyunji Lee, Sunyoung Ryu, Mi‐Hee Park, Sangchul Choi, Jisoo Park, Jongsun Park · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  33. Epigenetics and pharmacoepigenetics of rheumatic disorders
    Patricia Garrido Castro, Roberto Díaz‐Peña · 2025 · Elsevier eBooks
  34. The influence of biologic therapy on the capacity of regulatory T cells to restrain Th17 responses
    Jenny L. McGovern · 2012 · UCL Discovery (University College London)
  35. Potential crosstalk between the renin-angiotensin system and Neuropilin-1 pathways in experimental rheumatoid arthritis
    Nourhan E. Shahin, Nesrine S. El-Mezayen, Mahmoud M. Khattab · 2026 · European Journal of Pharmaceutical Sciences
  36. Expression et intérêt thérapeutique de l’interleukine 38 dans la polyarthrite rhumatoïde : simple antagoniste des interleukines 36 ou nouvel inhibiteur de l’inflammation ?
    Marie‐Astrid Boutet · 2016
  37. 関節リウマチ（RA）に対する低分子DMARDs（サラゾスルファピ リジン，ブシラミン，メトトレキサート）治療における，抗CCP抗体，リウマトイド因子の経時的変化および治療効果との関係の検討―RA患者を対象としたTRED (Three DMARDs) studyによる検討―
    古林 啓介, 二郎 山名, 佐々木 理恵, 岩橋 充啓, 征三 山名, 金 基哲 · 2014 · 臨床リウマチ